US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anti-Pandemic Concept

1,379.06

+4.600.33%

Number of Gainers:9

Number of Losers:9

Number of Flat:1

PE:- -

High:1,392.07

Open:1,378.91

Low:1,377.90

Close:1,374.47

Loading ...

OraSure Technologies received takeover bid from industry entrepreneur, sources say

European Equities Traded in the US as ADRs Edge Up in Monday Trading

MT Newswires Live

Gilead presents new data on twice-yearly lenacapavir for HIV prevention

Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for Hiv Prevention at Ias 2025

THOMSON REUTERS

Viiv Healthcare: Extends Voluntary Licensing Agreement With Medicines Patent Pool to Enable Access to Innovative Long-Acting Injectable Hiv Treatment

THOMSON REUTERS

Gilead price target raised to $114 from $105 at Leerink

AstraZeneca shares show signs of life after successful trials of hypertension drug

Gilead Sciences Secures FDA Approval for Yeztugo as HIV Prevention PrEP and Pursues Accelerated Regulatory Reviews Globally

Johnson & Johnson Receives FDA Approval for Updated Varipulse™ Platform Irrigation Rate

THOMSON REUTERS

Astrazeneca's Phase 3 Trial of Baxdrostat in Hypertension Meets Primary, Secondary Endpoints

MT Newswires Live

AstraZeneca announces BaxHTN trial met all primary, secondary endpoints

BUZZ-Leerink Partners raises PT on Gilead, citing HIV treatments prospects

NanoViricides: Design of Adaptive Clinical Trial Protocol for Treatment of Mpox Virus Clade Ia and Ib Infections and Disease Is Nearly Complete

THOMSON REUTERS

NanoViricides Inc. Nears Completion of Phase II Clinical Trial Design for Novel MPox Treatment NV-387

WHO recommends Gilead's twice-yearly injection for HIV prevention

BRIEF-World Health Organization Recommends Injectable Lenacapavir For HIV Prevention

Who Recommends Injectable Lenacapavir for Hiv Prevention

THOMSON REUTERS

World Health Organization: Recommends Public Health Approach to Hiv Testing Using Hiv Rapid Tests to Support Delivery of Long-Acting Injectable Prep

THOMSON REUTERS

Moderna (NasdaqGS:MRNA) Added to Russell Midcap Indexes

Simply Wall St.

3 Dividend Growth Stocks to Buy and Hold

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK4568/news?page=6"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1379.0648,"timestamp":1752868799999,"preClose":1374.4666,"halted":0,"volume":95962727,"delay":0,"changeRate":0.003345,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Market Closed","change":4.598267,"latestTime":"07-18 16:00:00 EDT","open":1378.9058,"high":1392.0709,"low":1377.9001,"amount":6205677126.969449,"amplitude":0.01031,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1753084800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.647019,"peRate":21.146563,"turnoverRate":0.006269,"increases":9,"decrements":9,"flats":1,"marketCap":1137445199268.5,"floatMarketCap":1116746960372.5},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1392.0709,"amplitude":0.01031,"preClose":1374.4666,"low":1377.9001,"pbRate":"3.647019","latestPrice":1379.0648,"volume":95962727,"delay":0,"open":1378.9058,"prevYearClose":1274.8187,"prevWeekClose":1397.679,"prevMonthClose":1377.5769,"prevQuarterClose":1377.5769,"fiveDayClose":1397.679,"twentyDayClose":1359.4229,"sixtyDayClose":1350.4775,"secType":"PLATE","market":"US","turnoverRate":0.006269,"peRate":21.146563,"marketCap":1137445199268.5,"floatMarketCap":1116746960372.5,"timestamp":1752868799999,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":9,"down":9,"flat":1},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:6,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2551803451","title":"OraSure Technologies received takeover bid from industry entrepreneur, sources say","url":"https://stock-news.laohu8.com/highlight/detail?id=2551803451","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551803451?lang=en_us&edition=fundamental","pubTime":"2025-07-14 23:57","pubTimestamp":1752508629,"startTime":"0","endTime":"0","summary":"OraSure Technologies received takeover bid from industry entrepreneur, sources sayBy Svea Herbst-BaylissNEW YORK, July 14 (Reuters) - Prominent healthcare entrepreneur Ron Zwanziger approached medical","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nL1N3T80R2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GB00BDT5M118.USD","LU0107464264.USD","IE00BZ1G4Q59.USD","LU2023250504.SGD","SGXZ57979304.SGD","LU2298321311.HKD","TMO","LU1551013425.SGD","LU0097036916.USD","LU2433249047.HKD","BK4566","LU0266013472.USD","LU1988902786.USD","LU2357305700.SGD","LU1804176565.USD","SG9999001176.SGD","LU0122379950.USD","LU2063271972.USD","LU1712237335.SGD","BK4535","IE00BKVL7J92.USD","LU0557290698.USD","IE000M9KFDE8.USD","LU2265009873.SGD","BK4585","LU0320765059.SGD","LU2237957902.USD","LU0390134368.USD","BK4533","LU0289739343.SGD","OSUR","LU0316494557.USD","IE00B2B36J28.USD","BK4548","LU0672654240.SGD","LU2244417387.USD","DHR","ABT","LU2125909247.SGD","LU1720051017.SGD","BK4568","LU1061106388.HKD","LU1854103824.USD","LU2125909759.SGD","BK4581","IE00B4R5TH58.HKD","LU1691799644.USD","LU0943347566.SGD","LU2133065610.SGD","IE00B19Z8W00.USD"],"gpt_icon":0},{"id":"2551187656","title":"European Equities Traded in the US as ADRs Edge Up in Monday Trading","url":"https://stock-news.laohu8.com/highlight/detail?id=2551187656","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551187656?lang=en_us&edition=fundamental","pubTime":"2025-07-14 23:13","pubTimestamp":1752506016,"startTime":"0","endTime":"0","summary":"European equities traded in the US as American depositary receipts edged up Monday with the S&P Europe Select ADR Index at 1,495.3, gaining 0.1% after erasing earlier losses.From continental Europe, the gainers were led by semiconductor company Sequans Communications  and biopharmaceutical company Cellectis , which surged 25% and 9.4% respectively. They were followed by biopharmaceutical company Genfit  and pharmaceutical company Ascendis Pharma , which were up 2.5% and 1.4% respectively.The decliners from continental Europe were led by biopharmaceutical company DBV Technologies  and biotech firm BioNTech , which fell 4.1% and 1.5% respectively. They were followed by petroleum refiner Equinor  and biopharmaceutical company argenx , which were down 1.2% and 1.1% respectively.From the UK and Ireland, the gainers were led by biopharmaceutical companies Biodexa Pharmaceuticals  and Mereo BioPharma Group , which rose 5.3% and 4.3% respectively. They were followed by biotech company Autolus ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4142","LU0109394709.USD","DBVT","BK4568","MREO","CLLS","DGE.UK","GNFT","BK4588","EQNR","BK4585","BK4139","BK4169","CUK","AUTL","DEO","AMRN","NCNA","BK4548","LU0320765992.SGD","BK4201","BK4535","BK4551","BNTX","LU0889565916.HKD","ASND","BDRX","BK4559","BK4082","TRIB","BK4141","BK4505","SQNS","ARGX"],"gpt_icon":1},{"id":"2551184925","title":"Gilead presents new data on twice-yearly lenacapavir for HIV prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2551184925","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551184925?lang=en_us&edition=fundamental","pubTime":"2025-07-14 21:35","pubTimestamp":1752500110,"startTime":"0","endTime":"0","summary":"Gilead (GILD) Sciences announced that Gilead researchers and collaborators will present new Phase 3 PURPOSE trial data at IAS 2025 showing that twi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-presents-new-data-on-twice-yearly-lenacapavir-for-hiv-prevention-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-presents-new-data-on-twice-yearly-lenacapavir-for-hiv-prevention-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1674673428.USD","LU1066051498.USD","LU0289739699.SGD","BK4532","SG9999015945.SGD","IAS","BK4550","LU1571399168.USD","LU0320765992.SGD","BK4583","GILD","BK4009","IE00BSNM7G36.USD","LU1430594728.SGD","LU1585245621.USD","BK4566","LU0058720904.USD","IE00BZ1G4Q59.USD","SG9999015978.USD","LU1674673691.USD","LU2089984988.USD","LU0234570918.USD","IE00BKVL7J92.USD","BK4568","BK4578","LU1066053197.SGD","LU1839511570.USD","LU2087621335.USD","BK4139","LU2468319806.SGD","BK4585","LU2324357040.USD","LU0109394709.USD","IE00B3T34201.USD","BK4588","LU0889565916.HKD","LU1778281490.HKD","SG9999015952.SGD","IE00B19Z3581.USD","LU0823416689.USD","IE00B7SZLL34.SGD","BK4539","IE00B19Z3B42.SGD","IE0002270589.USD","SG9999015986.USD"],"gpt_icon":0},{"id":"2551771181","title":"Gilead Presents New Data on Twice-Yearly Lenacapavir (Yeztugo®) for Hiv Prevention at Ias 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2551771181","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551771181?lang=en_us&edition=fundamental","pubTime":"2025-07-14 21:30","pubTimestamp":1752499800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nTUASMMKJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999015945.SGD","LU1585245621.USD","BK4578","LU1778281490.HKD","LU0320765992.SGD","LU0234570918.USD","IE0002270589.USD","LU1571399168.USD","LU1066051498.USD","LU1839511570.USD","SG9999015978.USD","IE00B7SZLL34.SGD","LU0058720904.USD","SG9999015986.USD","IE00B19Z3581.USD","BK4139","IE00BZ1G4Q59.USD","GILD","BK4532","IE00B19Z3B42.SGD","LU0823416689.USD","LU0889565916.HKD","BK4566","LU1066053197.SGD","BK4550","IE00B3T34201.USD","IE00BKVL7J92.USD","BK4585","IE00BSNM7G36.USD","LU1430594728.SGD","LU1674673691.USD","LU1674673428.USD","LU0289739699.SGD","LU2087621335.USD","SG9999015952.SGD","BK4583","BK4588","LU2089984988.USD","BK4568","LU2324357040.USD","LU0109394709.USD","LU2468319806.SGD"],"gpt_icon":0},{"id":"2551181779","title":"Viiv Healthcare: Extends Voluntary Licensing Agreement With Medicines Patent Pool to Enable Access to Innovative Long-Acting Injectable Hiv Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2551181779","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551181779?lang=en_us&edition=fundamental","pubTime":"2025-07-14 21:29","pubTimestamp":1752499748,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nFWN3TB18X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999001176.SGD","SG9999002224.SGD","LU1057294990.SGD","IE00BBT3K403.USD","BK4592","IE00B19Z3B42.SGD","SG9999003800.SGD","LU0306807586.USD","IE0002270589.USD","GSK.UK","SG9999001176.USD","IE00BLSP4239.USD","LU1670756490.USD","LU1400636491.USD","IE000M9KFDE8.USD","LU0234572021.USD","LU0456855351.SGD","PFE","SG9999002232.USD","LU1883839398.USD","LU0203345920.USD","IE00BQJZX424.USD","LU0203347892.USD","LU0211331839.USD","LU1023059063.AUD","LU1400636574.HKD","LU0575583348.USD","BK4585","LU0985481810.HKD","BK4534","LU0289739699.SGD","BK4007","IE0034235071.USD","LU1066051498.USD","LU1481600234.SGD","LU0225284248.USD","SG9999011175.SGD","LU0109981661.USD","LU0868494617.USD","LU1046248800.SGD","BK4568","LU1481599808.USD","LU1645745479.HKD","BK4599","LU1064927863.SGD","IE00BLSP4452.SGD","LU0971552830.HKD","LU0306806265.USD","LU0170899867.USD","LU0225771236.USD"],"gpt_icon":0},{"id":"2551181958","title":"Gilead price target raised to $114 from $105 at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2551181958","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551181958?lang=en_us&edition=fundamental","pubTime":"2025-07-14 21:06","pubTimestamp":1752498406,"startTime":"0","endTime":"0","summary":"Leerink analyst David Risinger raised the firm’s price target on Gilead (GILD) to $114 from $105 and keeps an Outperform rating on the shares. The ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gilead-price-target-raised-to-114-from-105-at-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gilead-price-target-raised-to-114-from-105-at-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4583","IE00BKVL7J92.USD","IE00B19Z3B42.SGD","LU1674673691.USD","SG9999015952.SGD","LU1066051498.USD","BK4532","SG9999015986.USD","IE00BZ1G4Q59.USD","BK4550","LU1674673428.USD","LU1430594728.SGD","LU1571399168.USD","BK4585","IE00B3T34201.USD","LU0889565916.HKD","LU1778281490.HKD","LU1839511570.USD","LU2324357040.USD","BK4566","LU2468319806.SGD","LU1066053197.SGD","SG9999015978.USD","IE00BSNM7G36.USD","LU0289739699.SGD","LU2087621335.USD","IE00B7SZLL34.SGD","BK4578","LU2089984988.USD","LU0109394709.USD","LU0823416689.USD","LU1585245621.USD","SG9999015945.SGD","BK4568","IE0002270589.USD","BK4588","IE00B19Z3581.USD","LU0234570918.USD","LU0320765992.SGD","GILD","LU0058720904.USD"],"gpt_icon":0},{"id":"2551518972","title":"AstraZeneca shares show signs of life after successful trials of hypertension drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2551518972","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551518972?lang=en_us&edition=fundamental","pubTime":"2025-07-14 20:50","pubTimestamp":1752497400,"startTime":"0","endTime":"0","summary":"Positive high-level results in trials of its baxdrostat drug to treat hypertension provided AstaZeneca shares with a much-needed fillip on Monday.Having slumped almost 20% from March highs, AstraZeneca   stock was still trading in negative territory for 2025 until Monday's announcement placed it among the top performers across European bourses.\"Baxdrostat BaxHTN Phase III trials on patients with uncontrolled or treatment-resistant hypertension demonstrated a statistically significant and clinically meaningful reduction in mean-seated systolic blood pressure  compared with placebo after twelve weeks,\" the company said in a press release.Hypertension, also known as high blood pressure, affects 1.3 billion people worldwide and can lead to a higher risk of cardiac arrest, stroke, heart failure and kidney disease. AstraZeneca's executive vice president  for research and development, Sharon Barr, lauded the drug's \"potential to address a critical unmet need by targeting aldosterone dysregula","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2456880835.USD","BK4588","LU0889565916.HKD","BK4007","LU2236285917.USD","LU2417539215.USD","LU1829250122.USD","BK4568","LU0320765992.SGD","SMMT","BK4139","LU2488822045.USD","AZN","LU2462157665.USD","BK4585","LU0109394709.USD"],"gpt_icon":0},{"id":"2551554189","title":"Gilead Sciences Secures FDA Approval for Yeztugo as HIV Prevention PrEP and Pursues Accelerated Regulatory Reviews Globally","url":"https://stock-news.laohu8.com/highlight/detail?id=2551554189","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551554189?lang=en_us&edition=fundamental","pubTime":"2025-07-14 20:31","pubTimestamp":1752496270,"startTime":"0","endTime":"0","summary":"Gilead Sciences Inc. has received approval from the U.S. Food and Drug Administration  for Yeztugo as PrEP to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg. This approval marks a significant step in HIV prevention efforts. Additionally, Gilead has submitted applications for marketing authorization and EU-M4all with the European Medicines Agency  for the same medication, which are under expedited review. The company is also seeking regulatory approval for twice-yearly lenacapavir as PrEP in several countries, including Australia, Brazil, Canada, South Africa, and Switzerland, with plans for further filings in Argentina, Mexico, and Peru. This development aligns with Gilead's strategic partnership with The Global Fund to supply lenacapavir at no profit to reach up to two million people in supported countries over the next three years.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL9Djws4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999015945.SGD","LU1571399168.USD","LU1585245621.USD","LU2087621335.USD","IE00B7SZLL34.SGD","LU0234570918.USD","LU0058720904.USD","LU0889565916.HKD","IE00B19Z3B42.SGD","LU1430594728.SGD","GILD","IE00B19Z3581.USD","IE00BKVL7J92.USD","LU0289739699.SGD","IE00B3T34201.USD","LU1839511570.USD","BK4532","LU0320765992.SGD","BK4568","BK4550","IE00BSNM7G36.USD","LU1066051498.USD","LU1674673691.USD","IE00BZ1G4Q59.USD","BK4566","BK4583","LU2324357040.USD","LU1066053197.SGD","BK4139","BK4578","SG9999015978.USD","SG9999015986.USD","SG9999015952.SGD","LU0823416689.USD","LU1778281490.HKD","BK4588","BK4585","LU2089984988.USD","LU0109394709.USD","LU1674673428.USD","IE0002270589.USD","LU2468319806.SGD"],"gpt_icon":0},{"id":"2551623186","title":"Johnson & Johnson Receives FDA Approval for Updated Varipulse™ Platform Irrigation Rate","url":"https://stock-news.laohu8.com/highlight/detail?id=2551623186","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551623186?lang=en_us&edition=fundamental","pubTime":"2025-07-14 20:02","pubTimestamp":1752494569,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nFWN3TB13C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1066051811.HKD","LU1244550494.USD","LU2505996509.AUD","LU1057294990.SGD","LU1935042991.SGD","IE00B3PB1722.GBP","LU1280957306.USD","LU2347655156.SGD","LU2089984988.USD","BK4534","LU1261432733.SGD","LU1023059063.AUD","LU1196500208.SGD","BK4588","IE0009355771.USD","BK4550","LU1585245621.USD","LU1066051498.USD","IE00B4R5TH58.HKD","LU2602419157.SGD","IE00BDGV0183.EUR","LU1267930813.SGD","LU1032466523.USD","IE00B19Z3B42.SGD","LU0234572021.USD","LU0795875086.SGD","LU2129689605.HKD","LU1244550577.SGD","LU1059921491.USD","LU0114720955.EUR","SG9999002224.SGD","SG9999002232.USD","LU1718418525.SGD","IE0002141913.USD","IE00B42XCP33.USD","LU1066051225.USD","IE00BGHQF631.EUR","LU0792757196.USD","LU1894683264.USD","LU2129689514.USD","IE00BFTCPJ56.SGD","LU2430703251.USD","LU0985320562.USD","LU1914381329.SGD","LU1074936037.SGD","LU1221951129.SGD","IE00BFXG1179.USD","BK4568","JNJ","LU0640476718.USD"],"gpt_icon":0},{"id":"2551940183","title":"Astrazeneca's Phase 3 Trial of Baxdrostat in Hypertension Meets Primary, Secondary Endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2551940183","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551940183?lang=en_us&edition=fundamental","pubTime":"2025-07-14 19:37","pubTimestamp":1752493071,"startTime":"0","endTime":"0","summary":"Astrazeneca (AZN) said Monday that a phase 3 study of Baxdrostat in patients with uncontrolled or treatment-resistant hypertension met its primary and all secondary endpoints.Baxdrostat at two differe","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1829250122.USD","BK4585","LU0889565916.HKD","BK4588","LU0320765992.SGD","BK4007","LU2456880835.USD","LU2462157665.USD","AZN","BK4568","LU0109394709.USD","LU2417539215.USD","LU2236285917.USD"],"gpt_icon":0},{"id":"2551629188","title":"AstraZeneca announces BaxHTN trial met all primary, secondary endpoints","url":"https://stock-news.laohu8.com/highlight/detail?id=2551629188","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551629188?lang=en_us&edition=fundamental","pubTime":"2025-07-14 19:05","pubTimestamp":1752491121,"startTime":"0","endTime":"0","summary":"AstraZeneca (AZN) announced results from the BaxHTN Phase III trial showed baxdrostat at two doses demonstrated a statistically significant and cli...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/astrazeneca-announces-baxhtn-trial-met-all-primary-secondary-endpoints-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/astrazeneca-announces-baxhtn-trial-met-all-primary-secondary-endpoints-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2417539215.USD","AZN","LU1829250122.USD","LU2462157665.USD","LU2236285917.USD","LU0320765992.SGD","LU0889565916.HKD","BK4568","LU2456880835.USD","BK4007","BK4585","LU0109394709.USD","BK4588"],"gpt_icon":0},{"id":"2551690747","title":"BUZZ-Leerink Partners raises PT on Gilead, citing HIV treatments prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2551690747","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551690747?lang=en_us&edition=fundamental","pubTime":"2025-07-14 18:38","pubTimestamp":1752489536,"startTime":"0","endTime":"0","summary":"BUZZ-Leerink Partners raises PT on Gilead, citing HIV treatments prospects** Brokerage Leerink Partners raises PT on drugmaker Gilead Sciences GILD.O to $114 from $105 ** Brokerage says it does not anticipate any \"major top- or bottom-line surprises\" in GILD's earnings, ahead of its Q2 results likely to be reported in early August** Maintains \"outperform\" rating** The new price target represents a 3.97% upside to the stock's last close** Aside from earnings, brokerage says \"the central focus will be on two recent HIV PrEP and treatment pipeline developments\" ** Brokerage says GILD's recently approved twice-yearly injectable HIV PrEP, Yeztugo, can quickly and widely become available, considering its lower price compared to its once-daily PrEP drug, Descovy, and its efficacy even though unclear guidelines after U.S. top court ruling on preventative coverage and CMS ** Twenty of 30 brokerages rate the stock \"buy\" or higher, 10 \"hold\"; their median PT is $118.50 - data compiled by LSEG** U","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nL4N3TB0TF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GILD","LU0889565916.HKD","BK4550","BK4566","LU1674673691.USD","LU0289739699.SGD","SG9999015945.SGD","LU1585245621.USD","IE00BZ1G4Q59.USD","IE0002270589.USD","LU0823416689.USD","IE00B19Z3B42.SGD","LU2324357040.USD","BK4585","BK4139","BK4568","IE00BSNM7G36.USD","LU1066051498.USD","BK4578","BK4583","LU1839511570.USD","IE00B19Z3581.USD","LU0109394709.USD","LU1430594728.SGD","SG9999015986.USD","LU1066053197.SGD","SG9999015952.SGD","LU1778281490.HKD","BK4588","IE00B3T34201.USD","SG9999015978.USD","LU0234570918.USD","LU0320765992.SGD","LU2087621335.USD","LU2089984988.USD","LU2468319806.SGD","LU1674673428.USD","LU0058720904.USD","IE00BKVL7J92.USD","IE00B7SZLL34.SGD","BK4532","LU1571399168.USD"],"gpt_icon":0},{"id":"2551907480","title":"NanoViricides: Design of Adaptive Clinical Trial Protocol for Treatment of Mpox Virus Clade Ia and Ib Infections and Disease Is Nearly Complete","url":"https://stock-news.laohu8.com/highlight/detail?id=2551907480","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551907480?lang=en_us&edition=fundamental","pubTime":"2025-07-14 18:32","pubTimestamp":1752489168,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nFWN3T905H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4568","NNVC","BK4139"],"gpt_icon":0},{"id":"2551907464","title":"NanoViricides Inc. Nears Completion of Phase II Clinical Trial Design for Novel MPox Treatment NV-387","url":"https://stock-news.laohu8.com/highlight/detail?id=2551907464","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551907464?lang=en_us&edition=fundamental","pubTime":"2025-07-14 18:30","pubTimestamp":1752489033,"startTime":"0","endTime":"0","summary":"NanoViricides Inc., a publicly traded company focused on developing broad-spectrum antivirals, has announced that the design of its adaptive clinical trial protocol for treating MPox Virus Clade Ia and Ib infections with the novel drug NV-387 is nearing completion. The trial aims to gather data on safe and effective dosing regimens, the safety and tolerability of the drug, and its antiviral effectiveness. The adaptive, randomized, standard of care controlled trial will enroll approximately 80 patients and proceed in two parts. In the Phase IIa part, NV-387 will be compared with the standard of care over an initial six-day dosing period, with potential for extension based on patient outcomes. Currently, no drug is approved as effective for treating MPox. If NV-387 proves effective, it would be the first drug to demonstrate effectiveness against an orthopoxvirus in human clinical trials. Results of the trial are expected to provide crucial insights into the drug's safety and efficacy.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nNDL6lCy3f:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","NNVC","BK4139"],"gpt_icon":0},{"id":"2551909203","title":"WHO recommends Gilead's twice-yearly injection for HIV prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2551909203","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551909203?lang=en_us&edition=fundamental","pubTime":"2025-07-14 17:10","pubTimestamp":1752484246,"startTime":"0","endTime":"0","summary":"WHO recommends Gilead's twice-yearly injection for HIV preventionJuly 14  - The World Health Organization on Monday recommended Gilead's  GILD.O lenacapavir, a twice-yearly injection, for preventing HIV infection.  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nL4N3TB0O6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","LU1674673691.USD","LU1066051498.USD","BK4585","IE0002270589.USD","BK4550","IE00BSNM7G36.USD","LU0058720904.USD","LU2089984988.USD","BK4578","LU0234570918.USD","IE00BZ1G4Q59.USD","SG9999015978.USD","IE00B7SZLL34.SGD","GILD","LU1778281490.HKD","LU2087621335.USD","BK4139","LU0889565916.HKD","LU2468319806.SGD","LU0109394709.USD","LU1674673428.USD","LU0320765992.SGD","SG9999015986.USD","BK4568","SG9999015945.SGD","IE00B3T34201.USD","BK4583","LU0289739699.SGD","LU1839511570.USD","SG9999015952.SGD","BK4588","IE00B19Z3B42.SGD","LU1066053197.SGD","LU1585245621.USD","LU2324357040.USD","IE00B19Z3581.USD","LU1430594728.SGD","BK4532","LU0823416689.USD","IE00BKVL7J92.USD","BK4566"],"gpt_icon":0},{"id":"2551172909","title":"BRIEF-World Health Organization Recommends Injectable Lenacapavir For HIV Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2551172909","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551172909?lang=en_us&edition=fundamental","pubTime":"2025-07-14 17:03","pubTimestamp":1752483838,"startTime":"0","endTime":"0","summary":"BRIEF-World Health Organization Recommends Injectable Lenacapavir For HIV PreventionJuly 14  - World Health Organization:WHO RECOMMENDS INJECTABLE LENACAPAVIR FOR HIV PREVENTIONWORLD HEALTH ORGANIZATION: RECOMMENDS PUBLIC HEALTH APPROACH TO HIV TESTING USING HIV RAPID TESTS TO SUPPORT DELIVERY OF LONG-ACTING INJECTABLE PREPFurther company coverage: GILD.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nFWN3TA01I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1571399168.USD","IE00BKVL7J92.USD","LU1674673691.USD","LU1839511570.USD","IE00BSNM7G36.USD","IE00B7SZLL34.SGD","LU0234570918.USD","BK4583","LU1674673428.USD","GILD","LU0320765992.SGD","BK4566","BK4139","LU1066051498.USD","BK4568","LU2089984988.USD","SG9999015945.SGD","LU0823416689.USD","BK4588","IE0002270589.USD","LU1066053197.SGD","BK4585","IE00B19Z3B42.SGD","LU1430594728.SGD","BK4550","LU2468319806.SGD","SG9999015986.USD","LU2324357040.USD","SG9999015952.SGD","IE00B19Z3581.USD","IE00BZ1G4Q59.USD","LU1778281490.HKD","BK4532","SG9999015978.USD","LU0889565916.HKD","IE00B3T34201.USD","LU0289739699.SGD","LU0058720904.USD","LU2087621335.USD","LU1585245621.USD","LU0109394709.USD","BK4578"],"gpt_icon":0},{"id":"2551909364","title":"Who Recommends Injectable Lenacapavir for Hiv Prevention","url":"https://stock-news.laohu8.com/highlight/detail?id=2551909364","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551909364?lang=en_us&edition=fundamental","pubTime":"2025-07-14 17:00","pubTimestamp":1752483653,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nFWN3TA01I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["SG9999015945.SGD","BK4568","LU1066053197.SGD","LU0289739699.SGD","BK4139","LU1674673691.USD","LU0889565916.HKD","LU1839511570.USD","IE00B3T34201.USD","LU1674673428.USD","GILD","IE00B19Z3581.USD","BK4578","LU0058720904.USD","LU2468319806.SGD","SG9999015986.USD","LU0234570918.USD","BK4550","LU1430594728.SGD","BK4585","LU0823416689.USD","BK4588","LU2324357040.USD","LU0320765992.SGD","LU1778281490.HKD","BK4532","SG9999015978.USD","IE00B19Z3B42.SGD","BK4566","LU2087621335.USD","IE00BKVL7J92.USD","SG9999015952.SGD","LU1066051498.USD","LU0109394709.USD","LU1571399168.USD","IE0002270589.USD","LU1585245621.USD","BK4583","IE00BSNM7G36.USD","LU2089984988.USD","IE00B7SZLL34.SGD","IE00BZ1G4Q59.USD"],"gpt_icon":0},{"id":"2551096869","title":"World Health Organization: Recommends Public Health Approach to Hiv Testing Using Hiv Rapid Tests to Support Delivery of Long-Acting Injectable Prep","url":"https://stock-news.laohu8.com/highlight/detail?id=2551096869","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551096869?lang=en_us&edition=fundamental","pubTime":"2025-07-14 17:00","pubTimestamp":1752483653,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250714:nFWN3TA01I:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","LU0823416689.USD","LU0889565916.HKD","BK4578","IE00BSNM7G36.USD","LU0289739699.SGD","BK4550","LU1066053197.SGD","LU1430594728.SGD","LU1674673428.USD","LU2087621335.USD","LU0109394709.USD","IE00BKVL7J92.USD","SG9999015978.USD","LU0234570918.USD","GILD","LU0320765992.SGD","SG9999015986.USD","LU1778281490.HKD","LU1585245621.USD","IE00B7SZLL34.SGD","LU2089984988.USD","LU1571399168.USD","IE0002270589.USD","BK4588","IE00B19Z3B42.SGD","LU0058720904.USD","BK4139","LU1674673691.USD","LU1839511570.USD","IE00BZ1G4Q59.USD","BK4566","LU2324357040.USD","BK4583","BK4568","BK4532","IE00B3T34201.USD","LU2468319806.SGD","SG9999015952.SGD","SG9999015945.SGD","LU1066051498.USD","IE00B19Z3581.USD"],"gpt_icon":0},{"id":"2551911206","title":"Moderna (NasdaqGS:MRNA) Added to Russell Midcap Indexes","url":"https://stock-news.laohu8.com/highlight/detail?id=2551911206","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2551911206?lang=en_us&edition=fundamental","pubTime":"2025-07-13 01:24","pubTimestamp":1752341065,"startTime":"0","endTime":"0","summary":"Moderna (NasdaqGS:MRNA) recently experienced significant index changes, with the company being added to the Russell Midcap and Midcap Value indexes, while being dropped from several others. Over the last quarter, its share price recorded a notable rise of 28%, against a backdrop of a flat broader market. This performance could be partly influenced by these index adjustments, as they often affect institutional investment decisions. Additionally, developments such as expanded collaborations and...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mrna/moderna/news/moderna-nasdaqgsmrna-added-to-russell-midcap-indexes","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4534","BK4501","MRNA","BK4585","BK4139","BK4551","BK4588","BK4533","BK4532","BK4568","BK4548"],"gpt_icon":1},{"id":"2550976369","title":"3 Dividend Growth Stocks to Buy and Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2550976369","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550976369?lang=en_us&edition=fundamental","pubTime":"2025-07-12 18:40","pubTimestamp":1752316800,"startTime":"0","endTime":"0","summary":"Abbott Laboratories is a dividend growth machine that's known for consistency.AbbVie's dividend has more than quadrupled since 2013.Eli Lilly offers dividend growth and, more importantly, tremendous share price growth.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/07/12/3-dividend-growth-stocks-to-buy-and-hold/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["BK4585","BK4082","LU0868494617.USD","IE0002141913.USD","LU1057294990.SGD","LU2112291526.USD","ABT","LU0266013472.USD","BK4581","LU1989763427.SGD","LU0122379950.USD","LU2237957902.USD","IE0009355771.USD","BK4566","BK4533","IE00BFTCPJ56.SGD","LU2237957811.SGD","LU2089984988.USD","SGXZ23171101.USD","LU1989763690.USD","BK4568","LU1023059063.AUD","SG9999004303.SGD","IE00B4R5TH58.HKD","BK4588","IE00B2B36J28.USD","LU2133065610.SGD","LU1721429741.USD","IE00BJT1NW94.SGD","LU2468319806.SGD","SG9999002224.SGD","SG9999002232.USD","LU0234572021.USD","LU1691799644.USD","IE00BJJMRZ35.SGD","LU1061106388.HKD","LU1721429402.USD","LU1914381329.SGD","BK4504","BK4592","LU0170899867.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":12,"pageCount":6,"totalSize":237,"code":"91000000","status":"200"}]}}